ArticleFrontiers in immunology2025

Low rather than high interleukin-6 levels are associated with immune-related adverse events in cancer patients treated with immune checkpoint inhibitors.

Iñigo Les et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.